ANKE BIO(300009)2019-03-28 16:00Financial Performance - The company's operating revenue for 2018 was CNY 1,461,550,203.44, representing a 33.32% increase compared to CNY 1,096,268,315.12 in 2017[13]. - The net profit attributable to shareholders for 2018 was CNY 263,171,602.71, a decrease of 5.25% from CNY 277,742,623.46 in 2017[13]. - The net profit after deducting non-recurring gains and losses was CNY 269,143,111.57, which is a 7.86% increase from CNY 249,539,856.09 in 2017[13]. - The total assets at the end of 2018 were CNY 2,526,966,294.89, reflecting a 12.10% increase from CNY 2,254,142,921.42 at the end of 2017[13]. - The net assets attributable to shareholders increased by 14.45% to CNY 1,920,325,638.68 at the end of 2018 from CNY 1,677,857,506.11 at the end of 2017[13]. - The company reported a basic earnings per share of CNY 0.2638, down 5.28% from CNY 0.2785 in 2017[13]. - The cash flow from operating activities for 2018 was CNY 287,490,590.56, a slight increase of 2.45% from CNY 280,625,013.82 in 2017[13]. - The company achieved total operating revenue of CNY 1,461.55 million, a year-on-year increase of 33.32%[26]. - Operating profit was CNY 310.63 million, a decrease of 5.60% compared to the previous year[26]. - Total profit amounted to CNY 309.60 million, down 5.97% year-on-year[26]. - Net profit attributable to ordinary shareholders of the parent company was CNY 263.17 million, a decline of 5.25% from the previous year[26]. - Net profit attributable to ordinary shareholders after deducting non-recurring gains and losses was CNY 269.14 million, an increase of 7.86% year-on-year[26]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 1,050,319,818 shares[3]. - The company declared a cash dividend of 1.50 CNY per 10 shares, totaling 157,547,972.70 CNY for the year, which represents 100% of the distributable profit[111]. - The total distributable profit available for distribution was 430,006,953.81 CNY after accounting for the legal surplus reserve and previous profit distributions[112]. - The company has maintained a consistent cash dividend policy, with the cash dividends for the past three years being 82,140,182.40 CNY in 2016, 106,872,210.15 CNY in 2017, and 157,547,972.70 CNY in 2018[113][114][115]. - The cash dividend payout ratio for 2018 was 59.87% of the net profit attributable to ordinary shareholders[116]. - The company has not issued any bonus shares or additional shares from capital reserves in the current reporting period[111]. - The total number of shares for the cash dividend distribution is based on 1,050,319,818 shares[111]. Risks and Challenges - The company faces various risks including new drug research and development risks, national policy changes, and acquisition integration risks[3]. - The company faces risks related to new drug development, including high investment, long cycles, and potential market rejection, which could adversely affect profitability[100]. - The company is actively addressing risks from national policy changes that may impact drug sales regions and pricing, necessitating adjustments in operational strategies[101]. - The company acknowledges the risk of goodwill impairment from acquisitions, which could negatively impact future earnings if actual profits do not meet projections[103]. Research and Development - The company is focused on the biopharmaceutical industry, with a strategy that includes precision medicine and a full industry chain layout in gene testing and targeted cancer drug development[20]. - The company aims to expand its market presence through the development of innovative biopharmaceutical products and technologies[20]. - The company increased its investment in research and development, with a significant rise in development expenses by 94.74% due to clinical research projects[29]. - The company is focusing on the development of gene-engineered drugs and has made significant progress in clinical trials for several new drugs, including humanized monoclonal antibodies[32]. - The company is advancing the clinical trial research of PEGylated recombinant human growth hormone injection, with preparations for clinical summary and production application underway[54]. - The company is conducting clinical trials for multiple new products, including recombinant human growth hormone for idiopathic short stature and PEGylated recombinant interferon α2b for chronic hepatitis B and C[55]. Market Strategy - The company aims to enhance its market position by expanding into precision medicine and increasing investment in new products and technologies[28]. - The biopharmaceutical industry is experiencing upward demand due to aging population and increased health awareness, with the market size growing annually[27]. - The company has established a professional sales team and a nationwide sales network, covering over 3,000 hospitals[33]. - The company actively explores external development channels to support sustainable and stable growth[22]. - The company’s marketing department implemented targeted strategies to enhance sales efficiency and expand market share in a competitive environment[43]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared that all board members attended the meeting to review the report[2]. - The company has received an A-level rating in information disclosure from the Shenzhen Stock Exchange, reflecting its commitment to transparency and investor relations[47]. - The company is committed to improving its governance structure and internal controls to ensure sustainable development and risk management[97]. - The company has committed to providing accurate and complete information regarding the asset restructuring, ensuring no false records or misleading statements exist[117]. - The company has pledged to avoid any form of competition with the listed company during the period of being a shareholder, ensuring no financial or operational support is provided to competing entities[118]. Environmental and Social Responsibility - The company has actively engaged in charitable activities, including donations of medical supplies to schools and elderly care facilities[168]. - The company donated CNY 1 million to the Wenzhou Medical University Education Development Foundation, with CNY 100,000 donated in 2018 and CNY 10,000 to be donated annually from 2019 to 2027[167]. - The company established the "Anke Dream" grassroots employment scholarship, which will reward outstanding graduates who serve in remote areas or join the military, with a reward of CNY 5,000 per person[167]. - The company has continued to provide scholarships to several universities in Anhui Province, including Anhui Medical University and Anhui University[167]. - The company has established a photovoltaic power station that generated a total income of 117,683 RMB for 54 impoverished families[173]. Investment and Financial Management - The company raised a total of RMB 682,039,998.08 through a private placement for projects including the industrialization of recombinant human HER2 monoclonal antibody drugs and the expansion of a production line for recombinant growth hormone with an annual capacity of 20 million units[104]. - The company is actively managing its idle funds to ensure optimal returns through strategic investments[158]. - The company has engaged in multiple financial products with varying maturity dates, indicating a diversified investment strategy[159]. - The company plans to continue expanding its investment in financial products to optimize returns and manage liquidity effectively[158]. - The company has reported a total of 46.04 million yuan in returns from a financial product maturing on May 3, 2018[159].